Metastatic (AstraZeneca D533AC00001 MONETTE)

Study Information

Status: Active, Not Recruiting

Study Details

View study details on clinicaltrials.gov.

Locations

Greater Sacramento Valley

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

Description

This is an open-label, phase 2 study that aims to evaluate the efficacy and safety/tolerability of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma and primary or secondary resistance to PD-(L)1 inhibition.

Location: SIMR (Sacramento/Valley Area, Roseville, and Auburn)

Please contact: SIMR@sutterhealth.org about Metastatic (AstraZeneca D533AC00001 MONETTE)

Principal Investigator

Deepti Behl, MD

Co-Investigator(s)

Jaspreet K Dhillon, Medical Oncologist, Kristin N. Arreola, M.D., Rajeswari Chellappah, M.D., Vijay Suhag, M.D., Brian K. Kim, M.D, Sivakumar Reddy, M.D., Kristie A. Bobolis, M.D., Dron Gauchan, MD

Related Studies

Cancer Liquid Biopsy Monitoring Study

A study testing the clinical utility of liquid biopsy for monitoring Sutter patients treated for metastatic melanoma or lung c

Investigators: Deepti Behl, MD, Mohammed Kashani-Sabet, M.D.

COVID-19 Impacts on Cancer Care Management, Patient Experience and Care Costs

Project goals: To understand impacts of COVID-19 on cancer care management (detection, diagnosis, treatment), pt-reported experience, and cancer care costs.

Investigators: Su-Ying Liang, Ph.D., Monique de Bruin, M.D., MPH, Cheryl Stults, Ph.D.

Stupski Serious Illness Program Evaluation

Evaluate palliative care projects at seven healthcare organizations in the SF Bay Area.

Investigator: Sylvia Sudat, PhD

Impact of COVID-19 on Cancer Care Management

Study will enhance understanding of cancer care management due to COVID-19.

Investigators: Monique de Bruin, M.D., MPH, Su-Ying Liang, Ph.D.

Coverage, Price, and Reimbursement for Multigene Tests for Cancer and Related Conditions

Our objective is to examine “coverage, price, and reimbursement” for multigene tests broadly and for cancer-related indications.

Investigator: Su-Ying Liang, Ph.D.

Improving Cancer Care

Project will provide information about referrals to palliative care and way to enhance goals of care discussions for patients diagnosed with stage IV cancer.

Investigator: Su-Ying Liang, Ph.D.

Multilevel Study of Lung Cancer Screening Guidelines Implementation (MUST)

Provide insights into preventive services for lung cancer. This research will contribute to the concurrent progress in lung cancer screening with LDCT.

Investigator: Jiang Li, Ph.D., MPH

Implementing Universal Lynch Syndrome Screening Across Multiple Healthcare Systems: Identifying Strategies to Facilitate and Maintain Programs in Different Organizations Contexts

To describe and explain variations in Lynch syndrome (LS) screening implementation across healthcare systems and create a toolkit for implementing LS screening.

Investigators: External PI, Principal Investigator, Monique de Bruin, M.D., MPH, Su-Ying Liang, Ph.D.

Lung Cancer in Never Smokers: Incidence, Risk Factors and Molecular Characteristics in Asian American, Native Hawaiian, and Pacific Islander (AANHPI) Women

The goal of this project is to document incidence and risk factors for lung cancer by smoking status, among AANHPIs, focusing especially on female never smokers.

Investigators: External PI, Principal Investigator, Su-Ying Liang, Ph.D.

Using Electronic Health Records to Understand Pathways of Breast Cancer Screening and Care

To examine how EHR data can expand understanding of breast cancer pathways--screening to dx and tx.